InsiderSignal.AI

InsiderSignal.ai

CGON - Cg Oncology, Inc.

Insider Sale by Mulay James (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Mulay James, serving as Dir at Cg Oncology, Inc. (CGON), sold 15,600 shares at $73.01 per share, for a total transaction value of $1,138,956.00.

This sale represents a 100.00% decrease in Mulay James's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, April 17, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 20, 2026, 3 days after the trade was made.

Cg Oncology, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Mulay James

Dir

James Mulay is a Director at CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing bladder cancer therapeutics[[1]](https://app.boardroomalpha.com/profiles/people/A1106073-JAMES_MULAY)[[5]](https://www.quiverquant.com/news/CG+Oncology+Appoints+Christina+Rossi+to+Board+of+Directors). He also serves as a Director at Fulgent Genetics, Inc. (NASDAQ: FLGT), where he holds approximately 5,000 shares[[4]](https://fintel.io/n/mulay-james). Mulay has been actively involved in CG Oncology's capital structure, having exercised stock options and engaged in significant insider trading activity, with 8 sales totaling 68,359 shares for approximately $2,496,247 between September and October 2025[[5]](https://www.quiverquant.com/news/CG+Oncology+Appoints+Christina+Rossi+to+Board+of+Directors), and most recently selling 11,145 shares in January 2026[[8]](https://www.marketbeat.com/instant-alerts/cg-oncology-nasdaqcgon-sets-new-12-month-high-time-to-buy-2026-03-04/). Mulay's insider trading activity at CG Oncology reflects routine portfolio management and compensation-related dispositions as the company advances cretostimogene, its investigational bladder cancer therapeutic, following recent BLA (Biologics License Application) initiation[[5]](https://www.quiverquant.com/news/CG+Oncology+Appoints+Christina+Rossi+to+Board+of+Directors)[[6]](https://www.stocktitan.net/overview/CGON/). His directorship positions indicate involvement in corporate governance across the biotechnology sector, contributing to strategic oversight during critical developmental and commercialization phases[[1]](https://app.boardroomalpha.com/profiles/people/A1106073-JAMES_MULAY)[[2]](https://www.tipranks.com/experts/insiders/mulay-james).

View full insider profile →

Trade Price

$73.01

Quantity

15,600

Total Value

$1,138,956.00

Shares Owned

0

Trade Date

Friday, April 17, 2026

4 days ago

SEC Filing Date

Monday, April 20, 2026

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Cg Oncology, Inc.

Company Overview

No company information available
View news mentioning CGON

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5806244

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime